127 A novel find of a Feed NSPase Enzyme, Natugrain® TS, reducing finish pig hemorrhagic bowel syndrome mortality

Abstract

Abstract This study presents a novel find of a Feed NSPase Enzyme, Natugrain TS, reducing finish pig hemorrhagic bowel syndrome (HBS) mortality. A total of 3,750 weaned pigs (28 kg), (PIC 337 x Camborough), were used in a randomized complete block design with pen as the experimental unit, treatment as the fixed effect, and block as the random effect (25 pigs/pen x 5 treatments x 30 replications). Pigs were blocked by sex and weight and were fed mash corn/soy/DDGs diets formulated to meet or exceed current NRC (2012) recommendations. Treatments were T1= 0 g/MT Natugrain TS, T2= 100 g/MT Natugrain TS, T3= 150 g/MT Natugrain TS, T4= 200 g/MT Natugrain TS and T5= 250 g/MT Natugrain TS. At the finishing phase, Natugrain TS significantly decreased intestinal E. coli log 10 (7.12, 4.95, 4.02, 3.21 and 3.25 log 10, P < 0.05, respectively), significantly decreased intestinal lesion score (0–5 score) (4.21, 4.02, 2.98, 2.25 and 2.26, P < 0.05, respectively). Microbiota was analyzed in fresh, manually collected, rectum fecal samples. Microbiota was separated into prevalent in Natugrain TS control (0) and 200 g/ton. In the control treatment, there was a prevalence of Desulfoyibrio, Oscillospira, Campylobacter, Anearoctruncus, Mogibacterium and Brachyspirae, etc., while in the 200 g/ton treatment there was a prevalence of Synergistales, Burkolderiales, Dehabacteriaceae, Bifidobacterium, Roseburia, Lactobacillus and Bacilli, etc. Natugrain TS significantly decreased mortality (4.8, 3.6, 2.7, 1.9 and 2.1 %, P < 0.05, respectively), significantly decreased specifically HBS mortality (3.50, 1.98, 0.68, 0.40 and 0.46%, P < 0.05, respectively). In conclusion, Natugrain TS changed the microbiome by breaking down arabinoxylans, decreasing intestinal E. coli and intestinal lesion score, changing the microbiota to prevalent Bifidobacterium, Roseburia, Lactobacillus and Bacilli, and Natugrain TS up to 200 g/ton specifically decreasing hemorrhagic bowel syndrome mortality from 3.5% to 0.5%.